stockrowGrifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
Follow GRFS
Alert me
Grifols, S.A. (GRFS) P/S ratio
As of 6 November 2026, Grifols, S.A. (GRFS) trades at a P/S ratio of 0.7×. Over the past ten years it has ranged from 0.0× (June 2024) to 3.7× (January 2018); the current reading is higher than 19% of that period. That is below the Drug Manufacturers General industry median of 3.5× and below the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 0.7× | (0.32%) |
| FY2024 | 0.7× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.6× | 55.66% |
| FY2022 | 0.4× | 3.67% |
| FY2021 | 0.4× | (81.46%) |
| FY2021 | 2.1× | 2.76% |
| FY2020 | 2.0× | (30.91%) |
| FY2020 | 3.0× | 1.33% |
| FY2019 | 2.9× | 16.71% |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 0.6× | (10.93%) |
| Mar 2026 | 0.6× | (15.30%) |
| Dec 2025 | 0.7× | (10.84%) |
| Sep 2025 | 0.8× | 7.17% |
| 29 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| OGN Organon & Co. compare | 0.6× |
| GRFS Grifols, S.A. | 0.7× |
| AMRN Amarin Corporation PLC compare | 1.4× |
| SNY Sanofi compare | 1.9× |
| GSK GSK PLC Sponsored ADR compare | 2.2× |
| BMY Bristol Myers Squibb Company compare | 2.5× |
| NVO Novo Nordisk A/S compare | 3.4× |
| BIIB Biogen Inc. compare | 3.6× |
| NSRX Nasus Pharma Ltd. compare | — |
| Drug Manufacturers General industry median | 3.5× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on GRFS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement